Search

Displaying results 2291 - 2300 of 10000 in total
  1. Drug

    Modified vaccinia ankara

    go.drugbank.com/drugs/DB15483
    ApprovedInvestigational

    Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).[L42660,L42670]

  2. Drug

    Asenapine

    go.drugbank.com/drugs/DB06216
    ApprovedInvestigational

    Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with

  3. Drug

    Fezolinetant

    go.drugbank.com/drugs/DB15669
    ApprovedInvestigational

    [A259542] Fezolinetant was approved by the FDA in May 2023 under the brand name Veozah.[L46422] It was subsequently approved by the EMA in December 2023 for the same indication.[L50086] … [A259601] Although the pathophysiology of VMS is not fully understood, unpredictable fluctuation in estrogen levels is thought to be the main cause of VMS, as estrogen therapy has been one of the most

  4. Drug

    PPI-2458

    go.drugbank.com/drugs/DB05864
    Investigational

    Clinical development with previous fumagillin derivatives has been limited by their toxicity profile. … PPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed at specific molecular oncology targets.

  5. Drug

    Dalfopristin

    go.drugbank.com/drugs/DB01764
    Approved

    It is not effective against Enterococcus faecalis infections. … Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.

  6. Drug

    Fosphenytoin

    go.drugbank.com/drugs/DB01320
    ApprovedInvestigational

    It works by slowing down impulses in the brain that cause seizures.

  7. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126]

  8. Drug

    Benzyl benzoate

    go.drugbank.com/drugs/DB00676
    Approved

    Scabies is a skin infection caused by the mite sarcoptes scabiei. It is characterised by severe itching (particularly at night), red spots, and may lead to a secondary infection. … Benzyl benzoate is not the treatment of choice for scabies due to its irritant properties.

  9. Drug

    19-norandrostenedione

    go.drugbank.com/drugs/DB01434
    ExperimentalIllicit

    19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. … After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency.

  10. Drug

    Pembrolizumab

    go.drugbank.com/drugs/DB09037
    ApprovedInvestigational

    [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1. … It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation.